These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 14742804)

  • 1. Role of C-reactive protein in cardiovascular disease.
    Backes JM; Howard PA; Moriarty PM
    Ann Pharmacother; 2004 Jan; 38(1):110-8. PubMed ID: 14742804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-reactive protein (CRP)-lowering agents.
    Prasad K
    Cardiovasc Drug Rev; 2006; 24(1):33-50. PubMed ID: 16939632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Inflammation and C-reactive protein in cardiovascular disease].
    Munk PS; Larsen AI
    Tidsskr Nor Laegeforen; 2009 Jun; 129(12):1221-4. PubMed ID: 19521445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
    Sellmayer A; Limmert T; Hoffmann U
    Int Angiol; 2003 Mar; 22(1):15-23. PubMed ID: 12771851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Sattar N; Murray HM; McConnachie A; Blauw GJ; Bollen EL; Buckley BM; Cobbe SM; Ford I; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Murphy MB; Packard CJ; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG; Shepherd J;
    Circulation; 2007 Feb; 115(8):981-9. PubMed ID: 17283264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [C-reactive protein in cardiovascular risk evaluation].
    Fabijanić D; Banić M; Kardum D
    Lijec Vjesn; 2006; 128(5-6):167-74. PubMed ID: 16910418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-reactive protein: a new risk assessment tool for cardiovascular disease.
    Clearfield MB
    J Am Osteopath Assoc; 2005 Sep; 105(9):409-16. PubMed ID: 16239491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [C-reactive protein and atherothrombosis--a prognostic factor or a risk factor?].
    Yosef-Levi IM; Grad E; Danenberg HD
    Harefuah; 2007 Dec; 146(12):970-4, 996. PubMed ID: 18254451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
    Li JJ; Fang CH
    Med Hypotheses; 2004; 62(4):499-506. PubMed ID: 15050096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
    Field KM
    Pharmacotherapy; 2005 Oct; 25(10):1365-77. PubMed ID: 16185181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of C-reactive protein in coronary risk reduction: focus on primary prevention.
    Gotto AM
    Am J Cardiol; 2007 Mar; 99(5):718-25. PubMed ID: 17317380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does C-reactive protein predict cardiovascular events in women better than LDL?
    Stevermer JJ
    J Fam Pract; 2003 Mar; 52(3):185-6. PubMed ID: 12620166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [C-reactive protein: cardiovascular issues of an acute-phase protein].
    Amezcua-Guerra LM; Springall del Villar R; Bojalil Parra R
    Arch Cardiol Mex; 2007; 77(1):58-66. PubMed ID: 17500194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-reactive protein: a family of proteins to regulate cardiovascular function.
    Schwedler SB; Filep JG; Galle J; Wanner C; Potempa LA
    Am J Kidney Dis; 2006 Feb; 47(2):212-22. PubMed ID: 16431250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein.
    Koenig W
    Int J Cardiol; 2005 Feb; 98(2):199-206. PubMed ID: 15686768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen.
    Wilson AM; Ryan MC; Boyle AJ
    Int J Cardiol; 2006 Jan; 106(3):291-7. PubMed ID: 16337036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preprocedural statin therapy in percutaneous coronary intervention.
    Cahoon WD; Crouch MA
    Ann Pharmacother; 2007 Oct; 41(10):1687-93. PubMed ID: 17712042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD40 ligand: a novel target in the fight against cardiovascular disease.
    Vishnevetsky D; Kiyanista VA; Gandhi PJ
    Ann Pharmacother; 2004 Sep; 38(9):1500-8. PubMed ID: 15280513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.